Cite
HARVARD Citation
McKay, R. et al. (2015). Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 121 (15), pp. 2603-2611. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
McKay, R. et al. (2015). Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 121 (15), pp. 2603-2611. [Online].